Prescription Symtuza contains 4 antiretroviral medicines in 1 pill, darunavir, cobicistat, emtricitabine and tenofovir alafenamide. These 4 active ingredients in Symtuza work in 3 different ways to combat the proliferation of the HIV virus. Darunavir blocks the protease enzyme of the virus required to viral reproduction. Cobicistat is a booster to darunavir, slowing the breakdown of this medicine. Tenofovir alafenamide is converted to tenofovir in the body which blocks the activity of the HIV enzyme called reverse transcriptase, required for viral reproduction. Emtricitabine works in a simlar way to tenofovir.
Symtuza is not a cure for HIV but improves your body's natural defenses and reduces the risk of developing illnesses related to HIV.
Symtuza is used by adults and children over 12 years old (at least 88 pounds). The standard Symtuza dose is one tablet daily, always with food or a snack. Take Symtuza at the same time each day and do not miss a dose even if you feel good. Do not stop taking Symtuza unless directed by your physician.
Symtuza is a great if you are concerned with viral resistance. In studies, 75% of Symtuza patients achieved the viral reduction goal after 24 weeks of treatment.
In 2019, when comparing Symtuza cost to USA Symtuza coupon price, InsulinHub was found to offer a discount of approximately 50% in Symtuza savings.
Buy Symtuza from InsulinHub.com for the best Symtuza cost.
Information about Symtuza (Darunavir / Cobiciistat / Emtricitabine / Tenofovir alafenamide)
Symtuza is a combination medication containing four active ingredients: Darunavir (an HIV protease inhibitor), Cobicistat (a pharmacokinetic enhancer), Emtricitabine (a nucleoside reverse transcriptase inhibitor), and Tenofovir alafenamide (a prodrug of tenofovir, a nucleotide reverse transcriptase inhibitor). Symtuza is prescribed for the treatment of HIV-1 infection in both adults and children who weigh 40 kg or more. It works by preventing the replication of the HIV virus, helping to manage HIV and improve the immune system’s function.
Product Highlights
- Administered as part of a combination treatment to manage HIV-1 infection in adults and children weighing 40 kg or more. It helps reduce viral load and maintain viral suppression in individuals with HIV.
Key Ingredient
- Darunavir
- Cobicistat
- Emtricitabine
- Tenofovir alafenamide
Key Benefits
- Symtuza combines four potent antiviral drugs, making it highly effective in reducing HIV viral load and increasing CD4+ cell counts in patients with HIV.
- Symtuza is taken once daily as a single tablet, which enhances patient adherence to treatment.
- The combination of ingredients is formulated to be well tolerated, with fewer side effects compared to older combination therapies.
- Combining drugs with different mechanisms of action reduces the risk of HIV developing resistance to treatment.
Direction of Use
- Symtuza is taken orally in tablet form.
- The recommended dose is one tablet (containing 800 mg of Darunavir, 150 mg of Cobicistat, 200 mg of Emtricitabine, and 10 mg of Tenofovir alafenamide) once daily with food.
- If you miss a dose, take it as soon as possible, unless it's almost time for your next one. Do not double up on doses to make up for the missed one.
Safety Concerns
- Possible side effects include diarrhea, nausea, headache, fatigue, and abdominal pain. These are typically mild and transient.
- Serious side effects can include liver problems (e.g., hepatitis), kidney issues (e.g., acute renal failure), lactic acidosis, and severe skin reactions. Patients should have their liver and kidney function monitored regularly.
- Symtuza can interact with other medications, including certain antifungal drugs, anticonvulsants, and some antibiotics. It is essential to notify your healthcare provider of all the medications you are taking.
- Symtuza is categorized as a pregnancy category B drug, indicating no risk in animal studies but limited data in pregnant women. It is not known if it passes into breast milk, so breastfeeding while taking Symtuza should be discussed with a healthcare provider.
Avoid Symtuza (Darunavir / Cobiciistat / Emtricitabine / Tenofovir alafenamide) If
- Do not use Symtuza if you have a known allergy to Darunavir, Cobicistat, Emtricitabine, Tenofovir alafenamide, or any components of the medication.
- Symtuza should be avoided in individuals with severe liver disease, as it may exacerbate liver problems.
- Patients with severe renal impairment (eGFR less than 30 mL/min) should not use Symtuza.
- While Symtuza is generally considered safe for use during pregnancy when prescribed by a doctor, it should only be used if the benefits outweigh the risks. Always speak with your healthcare provider if you are pregnant or planning to conceive.
- Symtuza should be avoided if you are taking certain medications, such as rifampin or certain anticonvulsants (e.g., carbamazepine, phenytoin), as these may decrease the effectiveness of the treatment.
